That didn't bother me at all... I'd rather that than a plumped out report and high admin costs.The 1000 soil sample assays due, the cash backing and actively seeking new projects more than justify it's current $3 million m/c io.
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status